Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069004591> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W2069004591 endingPage "793" @default.
- W2069004591 startingPage "793" @default.
- W2069004591 abstract "FDA in March approved bendamustine hydrochloride for injection, an alkylating agent from Cephalon Inc., for the treatment of chronic lymphocytic leukemia (CLL). The product will be marketed in the United States as Treanda. The American Cancer Society estimates that more than 15,000 new cases of CLL will be diagnosed in the United States this year, and about 4,400 Americans will die of the disease. Bendamustine is the first new molecular entity indicated for the treatment of the disease since 2001, Cephalon stated. In clinical trials, patients with CLL who were treated with bendamustine had a median progression-free survival time of 18 months, compared with 6 months for patients treated with chlorambucil, another alkylating agent. The FDA-approved labeling for bendamustine recommends that the drug be administered on the first and second days of a 28-day treatment cycle, with the treatment repeated for up to six cycles. The recommended dosage is 100 mg/m2 infused intravenously over 30 minutes." @default.
- W2069004591 created "2016-06-24" @default.
- W2069004591 creator A5072793957 @default.
- W2069004591 date "2008-05-01" @default.
- W2069004591 modified "2023-09-25" @default.
- W2069004591 title "Treanda approved for chronic lymphocytic leukemia" @default.
- W2069004591 doi "https://doi.org/10.2146/news080034" @default.
- W2069004591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18436722" @default.
- W2069004591 hasPublicationYear "2008" @default.
- W2069004591 type Work @default.
- W2069004591 sameAs 2069004591 @default.
- W2069004591 citedByCount "2" @default.
- W2069004591 countsByYear W20690045912015 @default.
- W2069004591 crossrefType "journal-article" @default.
- W2069004591 hasAuthorship W2069004591A5072793957 @default.
- W2069004591 hasConcept C126322002 @default.
- W2069004591 hasConcept C143998085 @default.
- W2069004591 hasConcept C2776694085 @default.
- W2069004591 hasConcept C2776755627 @default.
- W2069004591 hasConcept C2777866208 @default.
- W2069004591 hasConcept C2777938653 @default.
- W2069004591 hasConcept C2778461978 @default.
- W2069004591 hasConcept C2781442060 @default.
- W2069004591 hasConcept C535046627 @default.
- W2069004591 hasConcept C71924100 @default.
- W2069004591 hasConceptScore W2069004591C126322002 @default.
- W2069004591 hasConceptScore W2069004591C143998085 @default.
- W2069004591 hasConceptScore W2069004591C2776694085 @default.
- W2069004591 hasConceptScore W2069004591C2776755627 @default.
- W2069004591 hasConceptScore W2069004591C2777866208 @default.
- W2069004591 hasConceptScore W2069004591C2777938653 @default.
- W2069004591 hasConceptScore W2069004591C2778461978 @default.
- W2069004591 hasConceptScore W2069004591C2781442060 @default.
- W2069004591 hasConceptScore W2069004591C535046627 @default.
- W2069004591 hasConceptScore W2069004591C71924100 @default.
- W2069004591 hasIssue "9" @default.
- W2069004591 hasLocation W20690045911 @default.
- W2069004591 hasLocation W20690045912 @default.
- W2069004591 hasOpenAccess W2069004591 @default.
- W2069004591 hasPrimaryLocation W20690045911 @default.
- W2069004591 hasRelatedWork W2011815025 @default.
- W2069004591 hasRelatedWork W2144395078 @default.
- W2069004591 hasRelatedWork W2163348695 @default.
- W2069004591 hasRelatedWork W2247136531 @default.
- W2069004591 hasRelatedWork W2248735241 @default.
- W2069004591 hasRelatedWork W2256304711 @default.
- W2069004591 hasRelatedWork W2332757001 @default.
- W2069004591 hasRelatedWork W2883739273 @default.
- W2069004591 hasRelatedWork W3024144110 @default.
- W2069004591 hasRelatedWork W4207041128 @default.
- W2069004591 hasVolume "65" @default.
- W2069004591 isParatext "false" @default.
- W2069004591 isRetracted "false" @default.
- W2069004591 magId "2069004591" @default.
- W2069004591 workType "article" @default.